Efficacy and Safety of Weekly Paclitaxel in Breast Cancer With Symptomatic Bone Marrow Infiltration

Abstract

Mme HAMON MichèleRadiologie et imagerie médicale M. HANOUZ Jean-Luc Anesthésiologie Réanimation et médecine Péri-opératoire M. HULET Christophe Chirurgie orthopédique et traumatologique M. HURAULT de LIGNY Bruno Éméritat jusqu'au 31/01/2020 Néphrologie M. ICARD Philippe Chirurgie thoracique et cardio-vasculaire M. JOIN-LAMBERT Olivier Bactériologie -Virologie Mme JOLY-LOBBEDEZ Florence Cancérologie M. JOUBERT Michael Endocrinologie Mme KOTTLER Marie-Laure Biochimie et biologie moléculaire M. LAUNOY Guy Epidémiologie, économie de la santé et prévention M. LE COUTOUR Xavier Epidémiologie, économie de la santé et prévention M. LE HELLO Simon Bactériologie-Virologie Mme LE MAUFF Brigitte Immunologie M. LEPORRIER Michel Éméritat jusqu'au 31/08/2020 Hématologie M.

High-dose continuous infusion ifosfamide in the treatment of bone marrow infiltration with severe thrombocytopenia in a patient with Ewing sarcoma: a case report

“…A French retrospective study showed the efficacy and feasibility of weekly, low dose paclitaxel in 26 patients with breast cancer BMI. [20] Similarly, analogous cases of breast cancer BMI have been successfully treated with continuous infusion doxorubicin [21] or weekly nabpaclitaxel [22]. On the other hand, a patient with neuroblastoma did not derive any benefit from combination therapy of standard dose topotecan and cyclophosphamide [23].…”

Clinical features and treatment of bone marrow metastasis

“…Metastatic bone marrow cancer is a systemic, incurable disease with a poor prognosis which indicates that the patient is at an advanced stage. The median survival time of bone marrow metastatic carcinoma was 1.5–3 months ( 18 ). The reasons for the poor treatment outcomes were as follows: i) Patients who had received chemotherapy several times could have developed resistance to the tumour and patients with BMMs had poor bone marrow tolerance; therefore chemotherapeutic drugs which caused lower myelosuppression and required appropriate reductions in their dose were required to be selected as a treatment; ii) patients with poor body condition (with anaemia and thrombocytopenia) were prone to systemic infections, bleeding and other complications; iii) patients with an unknown primary focus could not be effectively treated with an antitumor therapy.…”